Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 32Metastatic Castration-resistant Prostate Cancer 3Prostatic Diseases 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Urogenital Neoplasms 1Thrombocytopenia 1Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Liver Neoplasms 1High-Risk Localized Prostate Cancer 1Glioma 1Glioblastoma 1Genital Neoplasms, Male 1Genital Diseases, Male 1Disease 1Cytopenia 1Carcinoma, Hepatocellular 1Carcinoma 1Astrocytoma 1Anemia 1

Interventions

padeliporfin 5pembrolizumab 1palladium-bacteriopheophorbide 1ixabepilone 1Therapeutics 1Radiotherapy 1Radiation Dose Hypofractionation 1Pluvicto 1Nivolumab 1Ipilimumab 1Gemcitabine 1Cisplatin 1Chemical Fractionation 1Biopsy, Needle 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Genital Neoplasms, Male × Pluvicto × Clear all
NCT05150236 2023-12-15

ANZUP2001

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Unknown
93 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡